Cogent Biosciences announces updates results from SUMMIT

Cogent Biosciences (COGT) announced updated clinical results from the Open Label Extension OLE, portion of SUMMIT, a clinical trial evaluating bezuclastinib in patients with nonadvanced systemic mastocytosis. The OLE data are being presented at the 66th American Society of Hematology Annual Meeting & Exposition taking place December 7-10, 2024 in San Diego, CA. Updated clinical data presented today show: 56% mean improvement in Total Symptom Score at 24 weeks; 76% of patients demonstrated greater than50% reduction from baseline in MS2D2 Total Symptom Score with 88% of patients exceeding 30% reduction from baseline after 24 weeks; 49% mean improvement in MC-QoL Total Score at 24 weeks. Bezuclastinib showed rapid, deep, and sustained reductions in serum tryptase over the course of 24 weeks of treatment including: 89% of patients had greater than50% decrease in serum tryptase levels by four weeks of treatment; 95% of patients with baseline tryptase greater than or equal to20ng/mL achieved less than20ng/mL by week 24; 84% of patients with baseline serum tryptase greater than11.4ng/ml achieved less than11.4ng/mL by week 24.